Spero Therapeutics (SPRO) Tax Provisions (2023 - 2025)

Spero Therapeutics has reported Tax Provisions for 3 years, with the latest figure at $261000.0 in Q4 2025.

• For the quarter ending Q4 2025, Tax Provisions rose 190.0% year-over-year to $261000.0; the trailing twelve-month figure through Dec 2025 stood at $261000.0 (down 89.95% YoY), and the FY2025 full-year result was $261000.0, changed N/A from the prior year.
• Tax Provisions for Q4 2025 stood at $261000.0, up from -$290000.0 in the prior quarter.
• The five-year high for Tax Provisions was $2.2 million in Q3 2023, with the low at -$290000.0 in Q4 2024.
• Historically, Tax Provisions has averaged $571800.0 across 3 years, with a median of $290000.0 in 2024.
• Annual changes were most pronounced in 2024 — Tax Provisions slumped 174.94% — and 2025, when it surged 190.0%.
• Spero Therapeutics' Tax Provisions stood at $387000.0 in 2023, then slumped by 174.94% to -$290000.0 in 2024, then surged by 190.0% to $261000.0 in 2025.
• The last three Tax Provisions figures came in at $261000.0 (Q4 2025), -$290000.0 (Q4 2024), and $290000.0 (Q3 2024), per Business Quant data.